Is immunization necessary after therapy for acute lymphoblastic leukemia (ALL) has been completed?

Acute Lymphoblastic Leukemia (ALL)

The second year has been completed

New chair, new members and many more possibilities Among many other things, the last European Respiratory Society (ERS) International Congress in Munich brought changes to the ERS Junior Members Committee (JMC). The 3-year term of JMC representatives has seen Indre Butiene, who initiated the Committee 3 years ago, finish her tenure as chair, with Anders Bjerg, respiratory epidemiologist from Go...

“Rhetoric Teaching” is necessary for all of the university students?

A simple search for information sources shows that there are many researches and articles in the field of lecture method and comparison with other types of teaching methods. Interestingly enough, if not with certainty in all of these researches, at least in most of them, the result was in favor of non-lecturing. Previously, the authors emphasized the importance of rhetoric in a Persian letter (...

Rituximab as therapy for acute lymphoblastic leukemia.

DT Frontline treatment approaches for newly diagnosed ALL have evolved from “one size fits all” chemotherapy regimens to subtype-oriented chemotherapy programs. The traditional risk factors that influence selection of therapy primarily include characteristics of the host, such as age, and features of the disease, such as lineage (T-lymphoblastic, B-lymphoblastic, or Burkitt-type [mature B-cell]...

DETERMINATION OF A SHARED EPITOPE ON CELLS FROM ACUTE MYELOGENIC LEUKEMIA (AML) AND T-ACUTE LYMPHOBLASTIC LEUKEMIA ( T-ALL)

Two IgM monoclonal antibodies (MAb) with strong reactivity for granulocytes and to a lesser extent for lurkat cell lines were established by immunizing BALBI c mice with a histiocytic cell line (UY37). These two MAbs (designated as 6C9 and 4C4) reacted with blast cells of T-acute lymphoblastic leukemia (T-ALL) and acute myelogenous leukemia (AML) patients as well as leukemic cells from pat...